NCT03516227

Brief Summary

The major aim of this study is to investigate the effects of biofeedback assisted abdominal breathing training on improving the psychological and physiological distress in patients with ACI. In this randomized, controlled, single-blind trial, AIS patients were randomly assigned into experimental and control groups. The experimental group received four HRVBF training sessions. The control group received routine care. Repeated measures of HRV, Mini-Mental Status Examination (MMSE), Hospital Anxiety and Depression Scales (HADS), and Barthel Index for ADLs were collected prior to, and at one, and three months post-intervention.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2015

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 9, 2015

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 26, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 3, 2016

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

April 23, 2018

Completed
11 days until next milestone

First Posted

Study publicly available on registry

May 4, 2018

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

October 11, 2019

Completed
Last Updated

October 11, 2019

Status Verified

September 1, 2019

Enrollment Period

8 months

First QC Date

April 23, 2018

Results QC Date

May 28, 2018

Last Update Submit

September 21, 2019

Conditions

Outcome Measures

Primary Outcomes (5)

  • Changes From Baseline Psychological Distress (Anxiety and Depression) at 1 and 3 Months

    The hospital anxiety and depression scale was a 14-item ordinal scale, used for participants to self-rate their psychological distress related to anxiety (7 items) and depression (7 items). Items are scored 0(no distress) to 3 (serious distress). Based on the findings from previous studies, scoring at or higher than the cut-off point of 8 out of 21, identified those with anxiety or depression. The minimum and maximum values of both anxiety and depression are 0 and 21, respectively. The higher scores mean a worse outcome.

    baseline, 1-month, and 3-month visits

  • Changes From Baseline Cognitive Function at 1 and 3 Months

    The Mini-Mental State Examination (MMSE) was used to measure patients' cognitive function. MMSE includes eleven items and consists of five facets orientation (space and time, registration, attention and calculation, recall, and language). The minimum value is 0 and the maximum value is 30. Lower scores represent a worse cognitive function.

    baseline, 1-month, and 3-month visits

  • Changes From Baseline Capabilities of Activities of Daily Living at 1 and 3 Months

    The 10-item Barthel Index (BI) was used to measure participants' capabilities in activities of daily living (ADLs) (feeding, bathing, grooming, dressing, transfers, and toilet use). BI score ranges from 0 to 100 with lower scores indicating lower ADLs capabilities.

    baseline, 1-month, and 3-month visits

  • Changes From Baseline Autonomic Function (Time-domain of Heart Rate Variability) at 1 and 3 Months

    Heart rate variability (HRV) was used to represent the autonomic function and measured with Mind Media B.V. (-Nexus-10, Netherlands). Time-domain of HRV was analyzed using Kubios HRV software (Biosignal Analysis and Medical Imaging Group, Finland). Time-domain indices of HRV indices: standard deviation of normal to normal R-R intervals (SDNN) and root mean square of successive heartbeat interval differences (rMSSD), which were reported with the Unit of Measure "ms". The higher scores mean a better outcome.

    baseline, 1-month, and 3-month visits

  • Changes From Baseline Autonomic Function (Frequency-domain of Heart Rate Variability) at 1 and 3 Months

    Heart rate variability (HRV) was used to represent the autonomic function and measured with Mind Media B.V. (-Nexus-10, Netherlands). Frequency-domain of HRV was analyzed using Kubios HRV software (Biosignal Analysis and Medical Imaging Group, Finland). Frequency domain indices of HRV were low frequency (LF), high frequency (HF), and total power (TP), which were reported with the unit of Measure "ms\^2". The higher scores mean a better outcome.

    baseline, 1-month, and 3-month visits

Study Arms (2)

HRVBF

EXPERIMENTAL

Heart rate variability biofeedback

Behavioral: heart rate variability biofeedback

Control

NO INTERVENTION

Usual Care

Interventions

The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.

HRVBF

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients within one week of their first ever ischemic stroke, who were 20 years of age or older, and who were able to express themselves through oral or written communication.

You may not qualify if:

  • Patients diagnosed with cardiac arrhythmia, mental illness, dementia or Alzheimer's disease, or totally paralyzed and totally dependent on others for care

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Ischemic StrokePrimary Dysautonomias

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesAutonomic Nervous System Diseases

Results Point of Contact

Title
Dr. Yu-Ju Chen
Organization
National Defense Medical Center, Taiwan

Study Officials

  • Yu-Ju Chen, Ph.D.

    National Defense Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

April 23, 2018

First Posted

May 4, 2018

Study Start

November 9, 2015

Primary Completion

June 26, 2016

Study Completion

August 3, 2016

Last Updated

October 11, 2019

Results First Posted

October 11, 2019

Record last verified: 2019-09

Data Sharing

IPD Sharing
Will not share